

# VHC - Triple earnings in 2Q2022

VHC almost doubled its 2Q2022 revenue over last year to VND4,226.3bn (+80.4% YoY) and tripled net profit to VND784.1bn (+200.9% YoY). Revenue generated by the fillet segment grew the most with 84.6% YoY in 2Q2022, followed by Wellness segment (+48.1% YoY), by product segment (+47.1% YoY) and rice products from Sa Giang (+43.3% YoY). We note that the value-added products have not delivered good performance yet while both pangasius fillet segment and by-product segment recorded negative MoM revenue growth in June 2022. In terms of export markets, the US recorded the highest growth rate of 135.8% YoY in 2Q2022, followed by EU (+49.3% YoY). We note that Chinese market started to recover in June with 45.9% YoY growth. Overall, the chinese market recorded 8.3% YoY growth in 2Q2022.

#### VHC revenue by segment and by market

| Vilo revenue by Segment and by market |        |        |            |
|---------------------------------------|--------|--------|------------|
| Revenue (VND bn)                      | 2Q2021 | 2Q2022 | YoY growth |
| Pangasius fillet                      | 1,522  | 2,810  | +84.6%     |
| By-product                            | 490    | 721    | +47.1%     |
| Wellness                              | 156    | 231    | +48.1%     |
| Value-added product                   | 45     | 45     | 0.0%       |
| Shirmp chips                          | 72     | 85     | +2.9%      |
| Rice product                          | 22     | 33     | +43.3%     |
| Export turnover by market (VND bn)    | 2Q2021 | 2Q2022 | YoY growth |
| US                                    | 901    | 2,125  | +135.8%    |
| EU                                    | 359    | 536    | +49.3%     |
| China                                 | 387    | 419    | +8.3%      |

647

Source: VHC

ROW

2Q2022 gross margin improved to 25.9% (vs. 18.5% in 2Q2021) while SG&A expenses increased at a slower pace than top line growth, boosting EBIT (+213.4% YoY). We believe the high profitability recorded in 2Q2022 is boosted by higher ASP thanks to increasing domestic raw pangasius prices and strong bargaining power of VHC. Raw pangasius prices jumped by 46.8% YoY in 2Q2022 to as high asVND32,500/kg in April and May, while both fingerlings and breeding fish prices jumped by 66.2% YoY and 49.6% YoY, respectively in 2Q2022.

1,142

VHC's interest expenses increased to VND110.3bn on the back of higher short term debt which we believe the purpose is to finance working capital as business grew strongly.

Overall 1H2022 result of VHC is equivalent to 56.6% and 79.5% of our top and bottom line full year forecasts, respectively.

Raw pangasius prices cooled down in July by approx. 5.6% vs. June 2022 given the seasonality of the pangasius business. However prices remain 35.6% higher than last year and we believe this will continue to support VHC profitability in 3Q2022.

Manager, Research Department Gigi Nguyen Binh

giaonbt@acbs.com.vn

+76.6%



# **DISCLAIMER**

## Analyst Certification(s)

We, the author(s) of this report, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

### **Important Disclosures**

ACBS and/or an affiliate thereof (hereby collectively called ACBS) did or may seek to do business with companies covered in this report as its routine business. ACBS's proprietary trading accounts may have a position in such companies' securities. As a result, the investor should be aware that ACBS may have a conflict of interest from time to time.

ACBS produces a variety of research products including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research products, whether as a result of differing time horizons, methodologies, or otherwise.

### **Disclaimer**

This report is provided for information purposes only. ACBS makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this report. ACBS will not treat unauthorized recipients of this report as its clients. Prices shown (if any) are indicative and ACBS is not offering to buy or sell or soliciting offers to buy or sell any financial instrument. Without limiting any of the foregoing and to the extent permitted by law, in no event shall ACBS, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this report or its contents. Other than disclosures relating to ACBS, the information contained in this report has been obtained from sources that ACBS believes to be reliable, but ACBS does not represent or warrant that it is accurate or complete. The views in this report are subject to change, and ACBS has no obligation to update its opinions or the information in this report.

Some parts of this report reflect the assumptions, views and analytical methods of the analysts who prepared them, and ACBS is not responsible for any error of their works and assumptions. ACBS may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report.

The analyst recommendations in this report reflect solely and exclusively those of the author(s), and such opinions were prepared independently of any other interests, including those of ACBS. This report does not constitute personal investment advice or take into account the individual financial circumstances or objectives of the investors who receive it. The securities discussed herein may not be suitable for all investors. ACBS recommends that investors independently evaluate each issuer, securities or instrument discussed herein and consult any independent advisors they believe necessary. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results.

This report may not be distributed to the public media or used by the public media without prior written consent of ACBS. Otherwise it will be considered as illegal. The breacher shall compensate fully to ACBS any loss or damage which arises from such breach (if any).

In the event that the distribution and/or receipt of this report is prohibited by the investor's jurisdiction, the investor shall dismiss this report immediately otherwise it will be at his/her own risks.

ACBS does not provide tax advice and nothing contained herein should be construed to be tax advice. Accordingly, the investors should seek advice based on their particular circumstances from an independent tax advisor. This report may contain links to third-party websites. ACBS is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this report and is not incorporated by reference into this report. The inclusion of a link in this report does not imply any endorsement by ACBS. Access to any third-party website is at the investor's own risks, and the investor should always review the terms and privacy policies at third-party websites before submitting any personal information to them. ACBS is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

© Copyright ACBS (2022).All rights reserved. No part of this report may be reproduced in any manner without the prior written permission of ACBS.